EP1089709A1 - Icecream-type pharmaceutical formulation and process for preparing the same - Google Patents

Icecream-type pharmaceutical formulation and process for preparing the same

Info

Publication number
EP1089709A1
EP1089709A1 EP00921116A EP00921116A EP1089709A1 EP 1089709 A1 EP1089709 A1 EP 1089709A1 EP 00921116 A EP00921116 A EP 00921116A EP 00921116 A EP00921116 A EP 00921116A EP 1089709 A1 EP1089709 A1 EP 1089709A1
Authority
EP
European Patent Office
Prior art keywords
icecream
type
milk
formulation
egg yolk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00921116A
Other languages
German (de)
French (fr)
Other versions
EP1089709A4 (en
Inventor
Moon-Young Heo
Hyun-Pyo Kim
Hong-Seok Cheong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Biotechnology Research Institute
Original Assignee
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotechnology Research Institute filed Critical Mogam Biotechnology Research Institute
Publication of EP1089709A1 publication Critical patent/EP1089709A1/en
Publication of EP1089709A4 publication Critical patent/EP1089709A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form

Definitions

  • the present invention relates to a soft icecream-type pharmaceutical formulation and a process for preparing the same .
  • Antipyretics, antibiotics and vitamins have been conventionally formulated in the forms of tablet, capsule, liquid, injection solution and syrup.
  • the conventional dosage forms are, however, proven to be less satisfactory in the sense that they are not convenient for administering to children. Accordingly, particular attention should be paid in choosing the dosage forms, especially, orally administrable pharmaceutical formulations are selected under a careful consideration of taste and mouth feel in oral cavity.
  • many medicines and active ingredients are bitter in taste or else hold uncomfortable taste, rough or chalky feeling.
  • the pharmaceutical formulations of relatively easy administration for children such as chewable tablet, jelly-like tablet, granules, etc., have been developed. They are commercially available though these pharmaceutical formulations are not ideal in terms of children's affinity. Under the circumstances, there are strong reasons for exploring and developing new type of pharmaceutical formulation for children.
  • the present inventors have made efforts to develop an icecream-type pharmaceutical formulation which can be applied in drugs such as antipyretics, antibiotics and vitamins, and found that it provides excellent drug absorption with improved patient's drug compliance in light of easy oral application and high affinity.
  • the primary object of the present invention is, therefore, to provide an icecream-type pharmaceutical formulation.
  • the other object of the invention is to provide a process for preparing the icecream-type pharmaceutical formulation.
  • Another object of the invention is to provide icecream-type formulations of antipyretic, antibiotic and vitamin.
  • Figure 1 is a high performance liquid chromatography chromatogram of acetaminophen in blood.
  • Figure 2 is a graph showing blood level of tablet- type and icecream-type acetaminophen after oral administration.
  • Icecream-type pharmaceutical formulation of the present invention is prepared by the steps of: mixing egg yolk and milk with stirring until they are completely mixed; whipping cream until it is reduced to pulp and mixing it with the said mixture in a volume ratio of 9:1 to 5:5, more preferably 8:2 to 6:4, most preferably 7:3; adding drugs into the said mixture in a ratio of 0.1 to 20wt% and blending them; and, finally putting them into an icecream maker and formulating into a pharmaceutical formula by subjecting at the temperature range of 0°C to -10°C.
  • sugar and/or cocoa may be further added to the mixture of egg yolk and milk according to the patient's preference, and coconut hard fat may substitute for the egg yolk.
  • the milk includes soy bean milk, processed skim milk (containing 7.2% skimmed milk powder) and plain milk.
  • the cream includes: commercially available emulsion cream which can be obtained by the centrifuge of animal/vegetable oil; and, carboxymethylcellulose (CMC) solution.
  • CMC carboxymethylcellulose
  • the antipyretics include acetaminophen, aspirin, ibuprofen, ketoprofen and isopropyl-antipyrin, preferably acetaminophen and/or mixture thereofs
  • the antibiotics include amoxicillin, ampicillin, erythromycin, lincomycin, and cefalexin, most preferably amoxicillin
  • the vitamins include retinol acetate, cholecalciferol, tocopherol acetate, ascorbic acid, thiamme nitrate, riboflamin, pyridoxine hydrochloride, ⁇ icotinamide and cyanocobalamin.
  • Example 1 Preparation of icecream-type formulation containing an antipyretic of acetaminophen Example 1-1
  • An icecream-type antipyretic formulation was prepared in an analogous manner as in Example 1-1, except for employing the ingredients shown in Table 2 below.
  • An icecream-type antipyretic formulation was prepared in an analogous manner as in Example 1-1, except for employing the ingredients shown m Table 3 below.
  • An icecream-type antibiotic formulation was prepared m an analogous manner as in Example 1-1, except for employing the ingredients shown in Table 4 below.
  • An icecream-type antibiotic formulation was prepared in an analogous manner as in Example 1-1, except for employing tne ingredients shown in Table 5 below.
  • An icecream-type antibiotic formulation was prepared in an analogous manner as in Example 1-1, except for employing the ingredients shown in Table 6 below.
  • An icecream-type multi-vitamin formulation was prepared in an analogous manner as in Example 1-1, except for employing the ingredients of retinol acetate, cholecalciferol, tocopheroi acetate, ascorbic acid, th amine nitrate, ⁇ boflavm, py ⁇ doxine hydrochlo ⁇ de, nicotinamide and cyanocobalamm as shown in Table 7 below.
  • Table 7 The contents of icecream-type formulation containing vitamins
  • An icecream-type multi-vitamin formulation was prepared m an analogous manner as m Example 1-1, except for employing the ingredients of retinol acetate, cholecalci erol, tocopheroi acetate, ascorbic acid, nitrate, nooflavm, py ⁇ oxine hydrochlo ⁇ de, nicotinamide and cyanocobalamm as snown in Table 8 below.
  • Table 8 The contents o-i icecream-type formulation containing vitamins
  • Acute toxicities of icecream-type formulations of antipyretics, antibiotics, and vitamins prepared m Examples 1, 2 and 3 were investigated by employing 5 sets of male and female rats, which revealed that no mortal rat was detected up to the level of 5g/kg/day which is 500 times of antipyretics, 5000 times of antibiotics and 50000 times of vitamins m terms of their effective amounts.
  • the icecream-type formulation of present invention which comprises antipyretic, antibiotic, or vitamin as an active ingredient is formulated for orally applicable purpose, accordance with the conventional formulating method by containing surfactants, excipients, t ctorials, stabilizers, buffers, suspensions, lsotomc solution, and other additives, organic or inorganic carriers.
  • the icecream-type formulation may be administered to children in an oral dosage in an amount of 2 to 20mg/kg(20kg as a standard weight), while it may be varied depending on the type o drugs, medical treatments, diseases, patient's age and duration of medication.
  • the present invention provides an icecream-type pharmaceutical formulation and a process for preparing the same. Icecream-type pharmaceutical formulations prepared by the invention have higher drug compliance to children with easy administration and good absorption and thus may substitute for troches .

Abstract

The present invention relates to a soft icecream-type pharmaceutical formulation and a process for preparing the same. The icecream-type pharmaceutical formulation of present invention is prepared by the steps of mixing egg yolk, milk, and cocoa with stirring until the cocoa is completely dissolved in the mixture; whipping a cream until it is reduced to pulp and mixing it with the said mixture in a volume ratio of 9:1 to 5:5; adding drugs into the said mixture and blending them; and, putting them into an ice cream maker and formulating into a pharmaceutical formula. Since a soft ice cream-type-formulation of the invention has merits over conventional formulas in terms of taking preference and absorbtion efficacy in oral application, it can be used as an improved pharmaceutical formula for children and infants, while substituting for troches.

Description

ICECREAM-TYPE PHARMACEUTICAL FORMULATION AND PROCESS FOR PREPARING THE SAME
BACKGROUND OF THE INVENTION
field of the invention
The present invention relates to a soft icecream-type pharmaceutical formulation and a process for preparing the same .
Description of the Prior Art
Antipyretics, antibiotics and vitamins have been conventionally formulated in the forms of tablet, capsule, liquid, injection solution and syrup. The conventional dosage forms are, however, proven to be less satisfactory in the sense that they are not convenient for administering to children. Accordingly, particular attention should be paid in choosing the dosage forms, especially, orally administrable pharmaceutical formulations are selected under a careful consideration of taste and mouth feel in oral cavity. Unfortunately, many medicines and active ingredients are bitter in taste or else hold uncomfortable taste, rough or chalky feeling. With the recent development in pharmaceutical technology, to improve taste and/or mouth feel in oral cavity, the pharmaceutical formulations of relatively easy administration for children such as chewable tablet, jelly-like tablet, granules, etc., have been developed. They are commercially available though these pharmaceutical formulations are not ideal in terms of children's affinity. Under the circumstances, there are strong reasons for exploring and developing new type of pharmaceutical formulation for children. SUMMARY OF THE INVENTION
The present inventors have made efforts to develop an icecream-type pharmaceutical formulation which can be applied in drugs such as antipyretics, antibiotics and vitamins, and found that it provides excellent drug absorption with improved patient's drug compliance in light of easy oral application and high affinity.
The primary object of the present invention is, therefore, to provide an icecream-type pharmaceutical formulation.
The other object of the invention is to provide a process for preparing the icecream-type pharmaceutical formulation.
Another object of the invention is to provide icecream-type formulations of antipyretic, antibiotic and vitamin.
BRIEF DESCRIPTION OF THE DRAWINGS
The above and the other objects and features of the present invention will become apparent from the following descriptions given in conjunction with the accompanying drawings, in which:
Figure 1 is a high performance liquid chromatography chromatogram of acetaminophen in blood.
Figure 2 is a graph showing blood level of tablet- type and icecream-type acetaminophen after oral administration.
DETAILED DESCRIPTION OF THE INVENTION
Icecream-type pharmaceutical formulation of the present invention is prepared by the steps of: mixing egg yolk and milk with stirring until they are completely mixed; whipping cream until it is reduced to pulp and mixing it with the said mixture in a volume ratio of 9:1 to 5:5, more preferably 8:2 to 6:4, most preferably 7:3; adding drugs into the said mixture in a ratio of 0.1 to 20wt% and blending them; and, finally putting them into an icecream maker and formulating into a pharmaceutical formula by subjecting at the temperature range of 0°C to -10°C. In the preparation of the icecream-type formulation, sugar and/or cocoa may be further added to the mixture of egg yolk and milk according to the patient's preference, and coconut hard fat may substitute for the egg yolk. Further, the milk includes soy bean milk, processed skim milk (containing 7.2% skimmed milk powder) and plain milk. And, the cream includes: commercially available emulsion cream which can be obtained by the centrifuge of animal/vegetable oil; and, carboxymethylcellulose (CMC) solution. Though several pharmaceutical formulations of antipyretics, antibiotics or vitamins are illustrated in the Examples below, they do not specifically limit the drugs contained in the formulation. The antipyretics include acetaminophen, aspirin, ibuprofen, ketoprofen and isopropyl-antipyrin, preferably acetaminophen and/or mixture thereofs, the antibiotics include amoxicillin, ampicillin, erythromycin, lincomycin, and cefalexin, most preferably amoxicillin, and the vitamins include retinol acetate, cholecalciferol, tocopherol acetate, ascorbic acid, thiamme nitrate, riboflamin, pyridoxine hydrochloride, πicotinamide and cyanocobalamin.
The present invention is further illustrated in the following examples, which should not be taken to limit the scooe of the invention.
Example 1: Preparation of icecream-type formulation containing an antipyretic of acetaminophen Example 1-1
Sugar, cocoa, egg yolk and milk were weighed in the ratios shown in Table 1 below, and mixed with stirring until they were completely dissolved. Then, commercially available emulsion cream was whipped until it was reduced to pulp and mixed with the said mixture. And then, acetaminophen, an antipyretic, was added to the mixture, blended, and put in an icecream maker (Philips, HR2034) and subjected at a temperature of 0°C to -10°C, to give an icecream-type formula.
Table 1. The contents of icecream-type formulation containing acetaminophen
Example 1-2
An icecream-type antipyretic formulation was prepared in an analogous manner as in Example 1-1, except for employing the ingredients shown in Table 2 below.
Table 2. The contents of icecream-type formulation containing acetaminophen
Example 1-3
An icecream-type antipyretic formulation was prepared in an analogous manner as in Example 1-1, except for employing the ingredients shown m Table 3 below.
Table 3. The contents of icecream-type formulation containing acetaminophen
Example Preparation of icecream-type formulation containing an antibiotic of amoxicillin
Example 2-1
An icecream-type antibiotic formulation was prepared m an analogous manner as in Example 1-1, except for employing the ingredients shown in Table 4 below.
Table 4: The contents of icecream-type formulation containing amoxicillin
Example 2-2
An icecream-type antibiotic formulation was prepared in an analogous manner as in Example 1-1, except for employing tne ingredients shown in Table 5 below.
Table 5: The contents of icecream-type formulation containing amoxicillin
Example 2-3
An icecream-type antibiotic formulation was prepared in an analogous manner as in Example 1-1, except for employing the ingredients shown in Table 6 below.
Table 6: The contents of icecream-type formulation containing amoxicillin
Example Preparation of icecream-type formulation containing vitamins Example 3 - 1 :
An icecream-type multi-vitamin formulation was prepared in an analogous manner as in Example 1-1, except for employing the ingredients of retinol acetate, cholecalciferol, tocopheroi acetate, ascorbic acid, th amine nitrate, πboflavm, pyπdoxine hydrochloπde, nicotinamide and cyanocobalamm as shown in Table 7 below.
Table 7 : The contents of icecream-type formulation containing vitamins
example 3-2:
An icecream-type multi-vitamin formulation was prepared m an analogous manner as m Example 1-1, except for employing the ingredients of retinol acetate, cholecalci erol, tocopheroi acetate, ascorbic acid, nitrate, nooflavm, pyπαoxine hydrochloπde, nicotinamide and cyanocobalamm as snown in Table 8 below. Table 8 : The contents o-i icecream-type formulation containing vitamins
Example 4 : Measurement of Blood Level of Drugs
To measure the blood level of acetaminophen, male SD rats were cannulized in arteriae femoralis after the ether treatment. When the rats were come out of the ether, comm.ercially available acetaminophen tablet and icecream- type formulation were orally administered with an equal amount of lOOmg/kgBW as acetaminophen per each. Blood was collected in an equal interval and injected to high performance liquid chromatography (HPLC) working under the analysis condition below. The HPLC chromatogram of acetaminophen in blood is shown in Figure 1.
Condition for HPLC Analysis:
Column: Bonaapak C18 (Waters, U.S.A.)
Mobile phase: acetcnitrile : 1% acetate (1:9, v:v' flow rate - lml/min Detector: UV spectrophotometer (λ=254nm) Example 5: Changes in Blood Level of Acetaminophen
Changes in blood level of acetaminophen were monitored by the method illustrated in Example 4, after oral administration of 50g icecream-type formulation prepared in Example 2-2 (containing 500mg acetaminophen) and commercially available acetaminophen tablet (containing 500mg acetaminophen) in an amount of lOOmg/kg to experimental rats (s≤e.: Figure 2) . As shown in Figure 2, C^., for the icecream-type formulation containing acetaminophen (o) was shown- at 20min while tablet form(*) was at 30min, and the blood level of drug in the icecream- type formulation was 3 times as high as the tablet-type formulation .
Example 6: Changes in Blood Level of Amoxicillin
Changes in blood level of amoxicillin were monitored by the method illustrated in Example 4, after oral administration of 50g icecream-type formulation prepared in Example 2-2 (containing 500mg amoxicillin) and commercially available amoxicillin capsule (containing 500mg amoxicillin) in an amount of lOmg/kg to experimental rats.
As a result, it was clearly determined that both of the icecream-type formulation and capsule-type formulation of amoxicillin showed similar blood level curve.
Example 7 : Changes in Blood Level of Tocopheroi Acetate
Changes in blood level of tocopheroi acetate were monitored by the method illustrated in Example 4, after oral administration of 50g icecream-type formulation prepared in Example 3-2 ( containing 500mg tocopheroi acetate) and commercially available tocopheroi acetate tablet (containing 500mg tocopheroi acetate) in an amount of lmg/kg to experimental rats. As a result, ooth of the icecream-type formulation and tablet-type formulation of tocopheroi acetate showed similar blood level curve.
Acute Toxicity
Acute toxicities of icecream-type formulations of antipyretics, antibiotics, and vitamins prepared m Examples 1, 2 and 3 were investigated by employing 5 sets of male and female rats, which revealed that no mortal rat was detected up to the level of 5g/kg/day which is 500 times of antipyretics, 5000 times of antibiotics and 50000 times of vitamins m terms of their effective amounts.
The icecream-type formulation of present invention which comprises antipyretic, antibiotic, or vitamin as an active ingredient is formulated for orally applicable purpose, accordance with the conventional formulating method by containing surfactants, excipients, t ctorials, stabilizers, buffers, suspensions, lsotomc solution, and other additives, organic or inorganic carriers.
The icecream-type formulation may be administered to children in an oral dosage in an amount of 2 to 20mg/kg(20kg as a standard weight), while it may be varied depending on the type o drugs, medical treatments, diseases, patient's age and duration of medication.
As clearly illustrated and demonstrated as above, the present invention provides an icecream-type pharmaceutical formulation and a process for preparing the same. Icecream-type pharmaceutical formulations prepared by the invention have higher drug compliance to children with easy administration and good absorption and thus may substitute for troches . Although the preferred embodiments of the present invention have been disclosed for illustrative purpose, those who are skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.

Claims

WHAT IS CLAIMED IS:
1. An icecream-type pharmaceutical formulation.
2. The icecream-type formulation of claim 1, wherein the drug is antipyretic, antibiotic or vitamin.
3. The icecream-type formulation of claim 2, wherein the antipyretic is selected from the group consisting of acetaminophen, aspirin, - ibuprofen, ketoprofen and isopropylantipyrin .
4. The icecream-type formulation of claim 2, wherein the antibiotic is selected from the group consisting of amoxicillin, ampicillin, erythromycin, lincomycin and cefalexin.
5. The icecream-type formulation of claim 2, wherein the vitamin is retinol acetate, cholecalciferol, tocopheroi acetate, ascorbic acid, thiamine nitrate, riboflavin, pyridoxine hydrochloride, nicotinamide, cyanocobalamin or mixture thereofs .
6. A process for preparing icecream-type pharmaceutical formulation, which comprises the steps of: mixing egg yolk and milk with stirring until they are completely mixed; whipping cream and mixing it with the mixture in a volume ratio of 9:1 to 5:5; adding drugs into the said mixture in a ratio of 0.1 to 20wt% and blending them; and, putting them into an icecream maker and formulating into a pharmaceutical formula.
7. The process of claim 6, further comprising a step of mixing sugar and/or cocoa with the egg yolk and the milk.
8. The process of claim 6, wherein the egg yolk is suostituted with coconut harα fat.
9. The process of claim 6, wherein the milk is substituted with soy bean milk or processed skim milk.
10. The process of claim 6, wherein the cream is carboxymethylcellulose (CMC) solution or emulsion cream which is obtained by the centrifuge of animal/vegetable oil.
11. The process of "claim 6, wherein the drug is antipyretic, antibiotic or vitamin.
12. An icecream-type formulation containing antipyretic prepared by the process of claim 6, which comprises 3.0 to 18.0wt of sugar, cocoa, egg yolk, and cream per each; 0.2 to 10.0wt% acetaminophen; and, milk.
13. An icecream-type formulation containing antibiotic prepared by the process of claim 6, which comprises 3.0 to 18.0 wt% of sugar, cocoa, egg yolk, and cream per each; 0.2 to 10.0w% amoxicillin; and, milk.
14. An icecream-type formulation containing multi- vitamin prepared by the process of claim 6 which comprises
3.0 to 18.0wt% of sugar, cocoa, egg yolk, and cream per each; 0.002 to 0.1wt% retinol acetate; 0.0004 to 0.02wt% cholecalciferol; 0.02 to 1.0wt% tocopheroi acetate; 0.04 to 2.0wt% ascorbic acid; 0.0008 to 0.04wt% thiamine nitrate; 0.0008 to 0.04wt% riboflavm; 0.0012 to 0.06wt% pyridoxine hydrochloride; 0.008 to 0.4wt% nicotinamide; 0.000004 to 0.0002 cyanocobalamm; and, milk.
EP00921116A 1999-04-09 2000-04-07 Icecream-type pharmaceutical formulation and process for preparing the same Withdrawn EP1089709A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR9912520 1999-04-09
KR1019990012520A KR20000065822A (en) 1999-04-09 1999-04-09 Icecream-type Pharmaceutical Formulation and Process for Preparing the Same
PCT/KR2000/000321 WO2000061110A1 (en) 1999-04-09 2000-04-07 Icecream-type pharmaceutical formulation and process for preparing the same

Publications (2)

Publication Number Publication Date
EP1089709A1 true EP1089709A1 (en) 2001-04-11
EP1089709A4 EP1089709A4 (en) 2002-01-23

Family

ID=19579240

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00921116A Withdrawn EP1089709A4 (en) 1999-04-09 2000-04-07 Icecream-type pharmaceutical formulation and process for preparing the same

Country Status (6)

Country Link
EP (1) EP1089709A4 (en)
JP (1) JP2002541184A (en)
KR (1) KR20000065822A (en)
CN (1) CN1300208A (en)
AU (1) AU4146500A (en)
WO (1) WO2000061110A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049304A1 (en) * 2001-08-29 2003-03-13 Somani Jitendra Krishan Quiescently frozen ice products
US6896923B2 (en) 2002-11-07 2005-05-24 Good Humor-Breyers Ice Cream Frozen confection
CN100402030C (en) * 2006-01-05 2008-07-16 珠海联邦制药股份有限公司 Pharmaceutical composition containing amoxicillin and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1071017A (en) * 1965-07-07 1967-06-07 Georg Hipp Process for producing biologically active compositions
US4218482A (en) * 1979-02-05 1980-08-19 Detyzco, Inc. Frozen, nutritious pet food
US5290605A (en) * 1989-06-29 1994-03-01 Niva Shapira Sun-exposure nutritional supporting composition
US5525352A (en) * 1992-11-05 1996-06-11 Kontos; Angelos Confectionery delivery system for pharmaceutically active substances
WO1997006697A1 (en) * 1995-08-21 1997-02-27 Unilever N.V. Antioxidant comprising food products
WO1997032486A1 (en) * 1996-03-05 1997-09-12 Georgi Grigorov Popov Protein rich dietary ice cream
WO2000015047A1 (en) * 1998-09-15 2000-03-23 Korea Research Institute Of Bioscience And Biotechnology Composition containing neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-related diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002668B (en) * 1996-03-15 1997-04-14 N Process for addition of sterile gaseous nitrogen and pharmaceutically active substances to solid yoghurt.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1071017A (en) * 1965-07-07 1967-06-07 Georg Hipp Process for producing biologically active compositions
US4218482A (en) * 1979-02-05 1980-08-19 Detyzco, Inc. Frozen, nutritious pet food
US5290605A (en) * 1989-06-29 1994-03-01 Niva Shapira Sun-exposure nutritional supporting composition
US5525352A (en) * 1992-11-05 1996-06-11 Kontos; Angelos Confectionery delivery system for pharmaceutically active substances
WO1997006697A1 (en) * 1995-08-21 1997-02-27 Unilever N.V. Antioxidant comprising food products
WO1997032486A1 (en) * 1996-03-05 1997-09-12 Georgi Grigorov Popov Protein rich dietary ice cream
WO2000015047A1 (en) * 1998-09-15 2000-03-23 Korea Research Institute Of Bioscience And Biotechnology Composition containing neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-related diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0061110A1 *

Also Published As

Publication number Publication date
CN1300208A (en) 2001-06-20
EP1089709A4 (en) 2002-01-23
AU4146500A (en) 2000-11-14
WO2000061110A1 (en) 2000-10-19
KR20000065822A (en) 2000-11-15
JP2002541184A (en) 2002-12-03

Similar Documents

Publication Publication Date Title
US5374659A (en) Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
US8287897B2 (en) Bitterness-masking particulate jelly beverage
KR100354310B1 (en) Azithromycin Administration Method
US6485738B1 (en) Delivery system for enhanced bioavailability of nutrients and supplements
CN102014904A (en) Liquid formulation for deferiprone with palatable taste
EP3137167A1 (en) Foods, systems, methods, and kits for providing electrolyte replacement
US4792449A (en) Method for drug administration
KR970000043B1 (en) Nutritional supplement
EP1089709A1 (en) Icecream-type pharmaceutical formulation and process for preparing the same
US6793935B2 (en) Mineral supplement
JP2001509175A (en) A taste-masking composition for pharmaceuticals that is tasteless and unpalatable
EP0432700A2 (en) Use of lithium compounds for the treatment of combination skin
AU745008B2 (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
Pedersen Treatment of children with a single dose a day of sustained release theophylline.
WO2019140316A1 (en) Solid concentrated constipation treatment formulations
GB2605971A (en) Nutritional supplement and uses
WO1999040920A1 (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
JP2001261580A (en) Medicine of dissolution type in time of use
JP2001106641A (en) Intraoral medicine
JPS64927B2 (en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20011211

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 9/127 A, 7A 61K 9/133 B, 7A 23G 9/02 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030405

RBV Designated contracting states (corrected)

Designated state(s): DE FR GB